Market Failure? Lower Drug Prices Don't Improve Access In Rheumatoid Arthritis
'Perverse incentives' guide US pricing for rheumatoid arthritis drugs, stakeholders say at policy roundtable convened by Institute for Clinical and Economic Review.
You may also be interested in...
The partners are looking to create a compelling value proposition for the interleukin-6 inhibitor, approved by FDA to treat moderate to severe RA, by pricing it below the market-leading anti-TNFs.
FDA complete response letter seeks additional data on dosing and other safety concerns, delaying potential approval for an NDA that already had been pushed back three months. Interleukin-6 inhibitors sarilumab and sirukumab, now under review at FDA, both could obtain approval before baricitinib.
Companies employed collaborative outreach with payers to arrive at 'responsible' price for atopic dermatitis biologic.